Alpha-Substituted Fatty Acids for Distal Gut GLP-1 Activation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing oral fatty acids are minimally effective in inducing clinically relevant GLP-1 concentrations and improving glycemic control due to rapid deactivation by DPP-4, site-specific absorption in the upper intestine, incorporation into chylomicrons, and activation primarily on the vascular side of the gut lining, failing to target GPR40 receptors in the distal intestine, and requiring excessive doses for IBD treatment.

Innovation Solution

Structurally modified unsaturated fatty acids with α-substituents to enhance binding and activation of GPR40/120 receptors in the ileum and large intestine, potentially inhibiting DPP-4 activity, and administered orally to stimulate GLP-1 production and treat inflammatory bowel diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If long-chain omega-3 fatty acids are administered orally to stimulate GLP-1 production, then GPR40 and GPR120 receptors should be activated, but GLP-1 concentrations remain minimally effective due to rapid deactivation by DPP-4

Engineering Contradiction:

ImproveGLP-1 production stimulationVSAvoidGLP-1 half-life

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies preliminary action by co-administering a DPP-4 inhibitor before or with the fatty acid to prevent GLP-1 degradation in advance. This ensures that when GLP-1 is produced through GPR40/GPR120 activation, it remains active long enough to exert therapeutic effects, resolving the contradiction between stimulating production and maintaining duration.

Inventive Principle:

Principle #10Preliminary action

2Ease of operation

If oral fatty acids are administered, then they are absorbed in the upper small intestine, but they fail to target GPR40 receptors in the distal intestine where high concentrations are needed

Engineering Contradiction:

ImproveOral administrationVSAvoidTarget tissue distribution

Core Design Contradiction:

Ease of operationVSArea of stationary object

Solution Approach 1:

The patent applies local quality by modifying the fatty acid structure to create compounds with altered absorption characteristics that enable them to reach and concentrate in the distal intestine. The structural modifications (alpha-substituents, beta-heteroatoms) create molecules that resist premature absorption in the upper intestine while maintaining oral administrability, thus achieving both ease of operation and proper tissue distribution.

Inventive Principle:

Principle #3Local quality

3Reliability

If structurally modified fatty acids are used to improve GPR40 activation, then binding affinity increases, but the complexity of the compound structure increases

Engineering Contradiction:

ImproveReceptor binding affinityVSAvoidMolecular structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by systematically modifying specific parameters of the fatty acid structure (adding alpha-substituents, introducing beta-heteroatoms) to optimize receptor binding affinity. These are controlled, targeted modifications rather than random complexity increases, achieving improved reliability through deliberate parameter optimization.

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The modified fatty acids effectively increase GLP-1 secretion, improve glycemic control by reducing hyperglycemia and increasing insulin levels, and treat IBD by reducing inflammation and intestinal injury.

Implementation Method 1

GPR40, along with a related receptor GPR120/FFAR4, is also expressed on enteroendocrine cells (specialised cells of the gastrointestinal tract and pancreas with endocrine function) in the intestine and responds to ligand binding by increasing the secretion of incretins, such as glucagon-like peptide 1 (GLP-1)

Methodology Applied

Scientific EffectReceptor binding:

Implementation Method 2

GLP-1 is broken down within minutes of release from the gut, oral compounds that inhibit endogenous GLP-1 breakdown, such as dipeptidyl peptidase-4 (DPP-4) inhibitors

Methodology Applied

Scientific EffectEnzymatic hydrolysis: Hydrolysis

Data Source

PatentUS20260000632A1Structurally modified fatty acids for improving glycemic control and treating inflammatory bowel disease

Publication Date: 2026.01.01 NORTHSEA THERAPEUTICS BV

AI summary

The present disclosure provides a compound for use as an activator of enteroendocrine GLP-1 production, improving glycemic control, and treating inflammatory bowel disease, wherein the compound is a structurally modified unsaturated fatty acid with an α-substituent, either alone or in combination with one or more additional therapeutic agents.